Gotowe bibliografie tematyczne / Oncolytic Viral Therapy

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji
  6. Raporty organizacyjne

Gotowa bibliografia na temat „Oncolytic Viral Therapy”

Autor: Grafiati
Data publikacji: 3 czerwca 2025
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Oncolytic Viral Therapy”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Oncolytic Viral Therapy"

1

Zurkiya, Omar, and Suvranu Ganguli. "Viral Oncolytic Therapy." Journal of Clinical Interventional Radiology ISVIR 01, no. 02 (2017): 096–99. http://dx.doi.org/10.1055/s-0037-1602389.

Pełny tekst źródła
Streszczenie:
AbstractViral oncolysis broadly refers to the use of modified viruses to infect and subsequently lyse tumor cells. This concept arises from the observation that viral replication is itself effective in destroying tumor cells. This effect is then amplified by reinfection of adjacent tumor cells by the progeny virion released from lysed tumor cells. Herpes simplex virus 1 (HSV-1) has been the primary focus of current efforts in viral oncolysis. It is a double-stranded DNA virus that is a ubiquitous pathogen transmitted by direct mucosal contact. HSV-1 possesses several features well suited to vi
Style APA, Harvard, Vancouver, ISO itp.
2

Hackethal, Veronica. "Oncolytic Viral Therapy." Oncology Times 42, no. 11 (2020): 1–9. http://dx.doi.org/10.1097/01.cot.0000669692.29645.ac.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Karadimas, Thomas, Thien Huong Huynh, Chloe Chose, et al. "Oncolytic Viral Therapy in Osteosarcoma." Viruses 16, no. 7 (2024): 1139. http://dx.doi.org/10.3390/v16071139.

Pełny tekst źródła
Streszczenie:
Primary bone malignancies, including osteosarcoma (OS), are rare but aggressive. Current OS treatment, involving surgical resection and chemotherapy, has improved survival for non-metastatic cases but remains ineffective for recurrent or metastatic OS. Oncolytic viral therapy (OVT) is a promising alternative, using naturally occurring or genetically modified viruses to selectively target and lyse cancer cells and induce a robust immune response against remaining OS cells. Various oncolytic viruses (OVs), such as adenovirus, herpes simplex virus, and measles virus, have demonstrated efficacy in
Style APA, Harvard, Vancouver, ISO itp.
4

Vengadaragava Chary, Krishnan, and Anish Bharatwaj. "ONCOLYTIC VIRAL THERAPY IN CANCER THERAPEUTICS." Asian Journal of Pharmaceutical and Clinical Research 10, no. 10 (2017): 96. http://dx.doi.org/10.22159/ajpcr.2017.v10i10.19265.

Pełny tekst źródła
Streszczenie:
Objective: The aim of this study is to provide comprehensive information of oncolytic viral therapy, from the origin to present scenario.Methods: This observational study was conducted by the Department of Pharmacology, Saveetha Medical College, Chennai between July and December 2016. Date regarding ongoing oncolytic virotherapy trials was retrieved from clinical trial database, United States and Clinical trial registry forum, India. Tamilnogene approval details were obtained from the US-Food and Drug Administration approval new drug approval information.Results: Eleven ongoing trials in Phase
Style APA, Harvard, Vancouver, ISO itp.
5

Kim, Sang-In, Shyambabu Chaurasiya, Anthony K. Park, et al. "Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models." International Journal of Molecular Sciences 21, no. 19 (2020): 7326. http://dx.doi.org/10.3390/ijms21197326.

Pełny tekst źródła
Streszczenie:
Oncolytic viroimmunotherapy is an exciting modality that can offer lasting anti-tumor immunity for aggressive malignancies like colon cancer. The impact of oncolytic viruses may be extended by combining them with agents to prime a tumor for viral susceptibility. This study investigates vitamin D analogue as an adjunct to oncolytic viral therapy for colon cancer. While vitamin D (VD) has historically been viewed as anti-viral, our in vitro investigations using human colon cancer cell lines showed that VD does not directly inhibit replication of recombinant chimeric poxvirus CF33. VD did restric
Style APA, Harvard, Vancouver, ISO itp.
6

Haddad, Dana, and Yuman Fong. "Molecular imaging of oncolytic viral therapy." Molecular Therapy - Oncolytics 1 (2014): 14007. http://dx.doi.org/10.1038/mto.2014.7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Parker, Jacqueline Nuss, David F. Bauer, James J. Cody, and James M. Markert. "Oncolytic viral therapy of malignant glioma." Neurotherapeutics 6, no. 3 (2009): 558–69. http://dx.doi.org/10.1016/j.nurt.2009.04.011.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Advani, Sunil J., James J. Mezhir, Bernard Roizman, and Ralph R. Weichselbaum. "ReVOLT: radiation-enhanced viral oncolytic therapy." International Journal of Radiation Oncology*Biology*Physics 66, no. 3 (2006): 637–46. http://dx.doi.org/10.1016/j.ijrobp.2006.06.034.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Rahal, Ahmad, and Benjamin Musher. "Oncolytic viral therapy for pancreatic cancer." Journal of Surgical Oncology 116, no. 1 (2017): 94–103. http://dx.doi.org/10.1002/jso.24626.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Alvarez-Breckenridge, Christopher A., Jianhua Yu, Balveen Kaur, Michael A. Caligiuri, and E. Antonio Chiocca. "Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells." Advances in Virology 2012 (2012): 1–14. http://dx.doi.org/10.1155/2012/702839.

Pełny tekst źródła
Streszczenie:
Despite active research in virotherapy, this apparently safe modality has not achieved widespread success. The immune response to viral infection appears to be an essential factor that determines the efficacy of oncolytic viral therapy. The challenge is determining whether the viral-elicited immune response is a hindrance or a tool for viral treatment. NK cells are a key component of innate immunity that mediates antiviral immunity while also coordinating tumor clearance. Various reports have suggested that the NK response to oncolytic viral therapy is a critical factor in premature viral clea
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Oncolytic Viral Therapy"

1

Hardcastle, Jayson James. "Vstat120 modulates inhibits oncolytic viral therapy induced angiogenesis and innate pro-inflamatory response, augmenting oncolytic viral thereapy of glioblastom multiforme." The Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1305920551.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Watson, Margaret. "Characterizing a Novel Viral Sensitizer BI-D1870." Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/39364.

Pełny tekst źródła
Streszczenie:
Oncolytic viruses (OVs) are an emerging cancer therapy that use an oncotropic virus to selectively infect and kill cancer cells, as well as stimulate long-lasting anti-tumor immune responses. In order to achieve high therapeutic efficacy, OVs need sufficient replication within the tumor tissue to mediate these effects. However, OV’s infectivity varies between different tumors and the host’s immune system can rapidly clear the virus, hampering treatment efficiency. Oncolytic virus sensitizers are chemical compounds that specifically enhance OV’s infectivity and efficacy. In our lab, I found tha
Style APA, Harvard, Vancouver, ISO itp.
3

Moussavi, Maryam. "Pre-clinical treatment of prostate cancer using targeted oncolytic viral therapy." Thesis, University of British Columbia, 2011. http://hdl.handle.net/2429/33980.

Pełny tekst źródła
Streszczenie:
Prostate cancer is the most prevalent non-skin malignancy and the second leading cause of cancer-related mortality in North American men. Current therapies for patients with locally advanced or metastatic prostate cancer are largely palliative and non-curative. Oncolytic viral-therapy provides a new approach to efficiently target and kill cancer cells while sparing normal cells. Vesicular Stomatitis Virus (VSV) is an oncolytic virus, which can infect and kill cells that have defects in their cellular anti-viral interferon (IFN) response. In this study, enhanced IFN-sensitive VSV(AV3) strain w
Style APA, Harvard, Vancouver, ISO itp.
4

Meisen, Walter Hans. "Improving Oncolytic Viral Therapy for Primary and Metastatic Tumors in the Brain." The Ohio State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=osu1429187113.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Le, Thu-Ha. "Protein dynamics in responder and non-responder solid tumor xenografts during oncolytic viral therapy." kostenfrei, 2008. http://www.opus-bayern.de/uni-wuerzburg/volltexte/2009/3201/.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

FOSCHINI, Maria Giovanna. "Use of miRNA target sequences to control essential genes of HSV1-based oncolytic vectors." Doctoral thesis, Università degli studi di Ferrara, 2012. http://hdl.handle.net/11392/2389272.

Pełny tekst źródła
Streszczenie:
The principal aim of this research is to design a new oncolytic vector based on herpes simplex virus type 1 (HSV-1) that can selectively destroy the cancer cells, while reducing the risk of toxicity in surrounding tissue or in other tissues. One approach to design these vectors, in order to obtain a controlled viral replication and their spread only inside the tumor mass, is taking advantage of unique tissue-associated patterns of expression of microRNAs (miRNA). Recent studies have shown that some miRNAs are overexpressed and some are down-regulated in several cancer cells, compared with thei
Style APA, Harvard, Vancouver, ISO itp.
7

Abate-Daga, Daniel. "Estudios de factores que condicionan la sensibilidad del tratamiento con TK/GCV. Diseño de estrategias combinadas para potenciar la citotoxicidad de TK/GCV: Silenciamiento de genes antiapópticos y virus oncolíticos armados con TK." Doctoral thesis, Universitat Pompeu Fabra, 2009. http://hdl.handle.net/10803/7135.

Pełny tekst źródła
Streszczenie:
El sistema TK/GCV es, problamente, la estrategia suicida mejor caracterizada hasta el momento. No obstante, se desconocen muchos aspectos relacionados con su mecanismo de acción. Con el objetivo de indentificar condicionantes de la respuesta TK/GCV, realizamos un estudio comparativo de la expresión de genes y de las vías de señalización que se activan en células sensibles y en células resistentes al tratamiento. Así, pudimos asociar la actividad de la quinasa Chk1, y la expresión de genes involucrados en el control del ciclo celular, con una mayor respuesta al sistema suicida. Así mismo, deter
Style APA, Harvard, Vancouver, ISO itp.
8

Strauss, Robert. "Analysis of resistance of primary ovarian cancer cells to viral oncolysis." Doctoral thesis, Humboldt-Universität zu Berlin, Mathematisch-Naturwissenschaftliche Fakultät I, 2010. http://dx.doi.org/10.18452/16163.

Pełny tekst źródła
Streszczenie:
Auf Adenoviren (Ads) basierende Vektoren wurden als ein gezielter Anti-Krebs-Wirkstoff entwickelt, der erfolgversprechende Resultate in prä-klinischen Studien erzielen konnte. Solche onkolytischen Ads sind zwar in klinischen Studien generell als sicher eingestuft worden, konnten jedoch die therapeutischen Erwartungen nicht erfüllen. In dieser Doktorarbeit konnte, unter Verwendung der Genexpressionsprofile von Ovarialkarzinom-Zellen, der epitheliale Phänotyp als Hindernis für allgemein verwendete onkolytische Ads, die auf den Coxsackie- und Adenovirusrezeptor (CAR) oder CD46 ausgerichtet sind,
Style APA, Harvard, Vancouver, ISO itp.
9

Altomonte, Jennifer [Verfasser]. "Optimization of oncolytic viral therapy for hepatocellular carcinoma / Jennifer Altomonte." 2010. http://d-nb.info/101094097X/34.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Le, Thu Ha. "Protein dynamics in responder and non-responder solid tumor xenografts during oncolytic viral therapy." Doctoral thesis, 2008. https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-32016.

Pełny tekst źródła
Streszczenie:
VACV GLV-1h68 was reported as a diagnostic/therapeutic vector which enters, replicates in, and reveals the locations of tumors in mice. Furthermore, the effect on tumor colonization, on tumor growth, regression and eradication by VACV GLV-1h68 without the need of any known genes with anti-tumoral activities was determined. To investigate differential protein expression between infected tumor cells and corresponding tumors, as well as between infected tumor cells, between infected tumors, proteomics is particularly used, possibly contributing to the understanding oncolytic ability on the protei
Style APA, Harvard, Vancouver, ISO itp.

Książki na temat "Oncolytic Viral Therapy"

1

1958-, Harrington Kevin J., Pandha Hardev, and Vile Richard G, eds. Viral therapy of cancer. John Wiley & Sons, 2007.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Brenner, Malcolm K., and Mien-chie Hung. Cancer gene therapy by viral and non-viral vectors. Wiley Balckwell, 2014.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

(Editor), Richard G. Vile, and Hardev Pandha (Editor), eds. Viral Therapy of Cancer. John Wiley & Sons, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Hung, Mien-Chie, and Malcolm Brenner. Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Incorporated, John, 2014.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Hung, Mien-Chie, and Malcolm Brenner. Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Limited, John, 2014.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Hung, Mien-Chie, and Malcolm Brenner. Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Incorporated, John, 2014.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Cancer Gene Therapy by Viral and Non-Viral Vectors. Wiley & Sons, Incorporated, John, 2014.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Części książek na temat "Oncolytic Viral Therapy"

1

Thirukkumaran, Chandini, and Don G. Morris. "Oncolytic Viral Therapy Using Reovirus." In Gene Therapy of Cancer. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-561-9_31.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Thirukkumaran, Chandini, and Don G. Morris. "Oncolytic Viral Therapy Using Reovirus." In Methods in Molecular Biology. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2727-2_12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Lamfers, Martine L. M., Therese Visted, and E. Antonio Chiocca. "Oncolytic Viral Therapy for Glioma." In Progress in Neurological Surgery. KARGER, 2005. http://dx.doi.org/10.1159/000084480.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Miura, John T., and Jonathan S. Zager. "Intralesional Therapies: Oncolytic Viral Therapies, Immunostimulants." In Cancer Regional Therapy. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-28891-4_35.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Javed, Mohd, and Sisir Nandi. "Oncolytic Viral Therapy: A Promising Approach in Cancer Treatment." In Global Trends in Health, Technology and Management. Springer Nature Switzerland, 2024. https://doi.org/10.1007/978-3-031-75457-9_15.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Spiesschaert, Bart, and Saurabh Gautam. "Oncolytic Viruses and Viral Gene Therapy Vectors: Principles of Safety." In Bioprocess and Analytics Development for Virus-based Advanced Therapeutics and Medicinal Products (ATMPs). Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-28489-2_18.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Ayodele, Olubukola, and Lillian L. Siu. "New Drugs for Recurrent or Metastatic Nasopharyngeal Cancer." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_23.

Pełny tekst źródła
Streszczenie:
AbstractChemotherapy has been the backbone for the treatment of recurrent or metastatic nasopharyngeal carcinoma (RMNPC), which remains an incurable disease. Currently the most active area of therapeutic investigations in RMNPC is in immunotherapy, especially after the results of five anti-programmed death-1 (anti-PD-1) antibodies, i.e. pembrolizumab, nivolumab, camrelizumab, toripalimab and tislelizumab, have demonstrated monotherapy objective response rates of 21%–43%. Combinations using anti-PD1/L1 antibodies as backbone to evaluate their additivity or synergy with cytotoxic chemotherapy, m
Style APA, Harvard, Vancouver, ISO itp.
8

Ayyildiz, Orhan, and Yusuf Hekimoglu. "What Is Immunotherapy and History of Immunotherapy in Cancers." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.1.

Pełny tekst źródła
Streszczenie:
Immunotherapy, a transformative cancer treatment, harnesses the immune system’s inherent ability to combat neoplastic cells. Ancient medicine hinted at immunological principles, recognizing natural disease resistance and the body’s defensive capabilities. Over time, the understanding of the immune system evolved, with key contributions from early thinkers like Ibn Sina and later scientific pioneers like Ilya Mechnikov. The immune system, comprising innate and adaptive components, is vital in defending against pathogens and regulating cell proliferation, including cancerous cells. The concept o
Style APA, Harvard, Vancouver, ISO itp.
9

"Newcastle Disease Virus: Its Oncolytic Properties." In Viral Therapy of Human Cancers. CRC Press, 2004. http://dx.doi.org/10.1201/b14180-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

"Measles Virus: Improving Natural Oncolytic Properties by Genetic Engineering." In Viral Therapy of Human Cancers. CRC Press, 2004. http://dx.doi.org/10.1201/b14180-6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Oncolytic Viral Therapy"

1

Barreto, Everton Rodrigo, Rosana Maria Faria Vador, and Thalita Martins Ferraz Meneses. "Nurse performance in viral oncolytic therapy." In III SEVEN INTERNATIONAL MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/seveniiimulti2023-084.

Pełny tekst źródła
Streszczenie:
Introduction: Viral oncolytic therapy (VOT) is an emerging approach in cancer treatment, which is based on the selective replication of a viral vector inside cancer cells, triggering the death of tumor cells by lysis and the spread of new viral particles to the remaining adjacent malignant cells. However, special care is needed from nurses to manage immune-mediated side effects and provide support and education to patients and their families during treatment. Objectives: To survey the nurse's performance in the face of VOT; propose a model of Systematization of Nursing Care (SNC) with the main
Style APA, Harvard, Vancouver, ISO itp.
2

Elshourbagy, Tarek, and James Robert Brašić. "Oncolytic Viral Therapy with Gravity Approaching Zero to Ameliorate Glioblastoma Multiforme." In IECC 2024. MDPI, 2024. http://dx.doi.org/10.3390/proceedings2024100024.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Alvarez-Breckenridge, Christopher A., Jianhua Yu, Jason Pradarelli, et al. "Abstract 1514: Oncolytic viral therapy for glioblastoma induces robust natural killer cell activation." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1514.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Mostafa, Ahmed, Kathy Gratton, Keith A. Lawson, Zhong-Qiao Shi, Chandini Thirukkumaran, and Don G. Morris. "Abstract A12: PDL-1 blockade and Sunitinib enhance the efficiency of oncolytic viral therapy." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-a12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Elshourbagy, Tarek, and James Robert Brašić. "Amelioration of Glioblastoma Multiforme via the Combination of Simulated Microgravity and Oncolytic Viral Therapy." In International Electronic Conference on Cancers: New Targets for Cancer Therapies. MDPI, 2023. http://dx.doi.org/10.3390/iecc2023-14219.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Ogata, Hisanobu, Beibei Wang, Shoei Miyamoto, et al. "Abstract 4779: Coxsackievirus A11 as a novel oncolytic viral therapy for human colorectal cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4779.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Ogata, Hisanobu, Beibei Wang, Shoei Miyamoto, et al. "Abstract 4779: Coxsackievirus A11 as a novel oncolytic viral therapy for human colorectal cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4779.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

D’Souza, Alicia, Ryuhjin Ahn, GBM TeamLab, and Forest White. "1368 Characterizing changes in antigen presentation of glioblastoma tumors in response to oncolytic viral therapy." In SITC 39th Annual Meeting (SITC 2024) Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/jitc-2024-sitc2024.1368.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Contag, Pamela R. "Abstract CT155: Design of a dose escalation phase 1/2 trial for a novel combined cell and oncolytic viral therapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct155.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Liu, Jianrui, Jason Spurrel, Zhong Qiao Shi, WenQian Chen, and Don G. Morris. "Abstract 5355: Oncolytic viral therapy with immune modulation is an effective novel treatment strategy for non-small cell lung cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5355.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Oncolytic Viral Therapy"

1

Martuza, Robert L. Immunologic Approaches for Oncolytic Viral Therapy of Prostate Cancer. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada433864.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Oncolytic Viral Therapy” dla poszczególnych typów źródeł:
Artykuły w czasopismach
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii